PepMetics Technology Enabling the Control of Protein-Protein Interactions

Abstract

PepMetics technology is a platform for controlling protein-protein interactions (PPIs) through compounds that mimic α-helix and β-turn structures of proteins. These molecules are built on a steric scaffold with multiple attached side chains, offering properties similar to natural products while allowing excellent synthetic feasibility with stereo configuration control. This technology drives two core business areas: in-house drug discovery and collaboration with pharmaceutical companies. Two compounds from this platform have already entered clinical trials. PepMetics continues to evolve by integrating with emerging drug discovery technologies such as AI-based drug design, cyclic peptides, and AlphaFold. This approach is opening up a novel drug discovery targeting PPI control, potentially transforming undruggable targets into druggable ones and advancing the search for cures to previously incurable diseases.